Antiproteinuric effect of losartan in non-diabetic renal disease is not dependent on ACE insertion/deletion polymorphism

Kidney and Blood Pressure Research

Volumn 29, Issue 4, 2006, Pages 216-224

  Park, Hyeong Cheon ^a   Choi, Hoon Young ^a   Kim, Beom Seok ^a   Kang, Shin Wook ^a   Choi, Kyu Hun ^a   Ha, Sung Kyu ^a   Lee, Ho Yung ^a   Han, Dae Suk ^a  

^a Yonsei University   (South Korea)

Author keywords

Angiotensin converting enzyme gene polymorphism; Losartan; Nephropathy, non diabetic; Proteinuria

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; ATENOLOL PLUS CHLORTALIDONE; CHLORTALIDONE; CREATININE; DICHLOZID; DIPEPTIDYL CARBOXYPEPTIDASE; DOXAZOSIN; FUROSEMIDE; LOSARTAN; UNCLASSIFIED DRUG;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE REGULATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE DELETION; GENE INSERTION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HYPERTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEINURIA; SHORT COURSE THERAPY; STATISTICAL ANALYSIS; TREATMENT DURATION;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD PRESSURE; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; GENE DELETION; GENOTYPE; HUMANS; LOSARTAN; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; PREVALENCE; PROTEINURIA; TREATMENT OUTCOME;

EID: 33751168720     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000095736     Document Type: Article

References (41)

1. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, de Jong PE, de Zeeuw D, Shahinfar S, Ruggenenti P, Remuzzi G, Levey AS: Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001;60:1131-1140.
2. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004;65:2309-2320.
3. Parving HH, Andersen S, Jacobsen P, Christensen PK, Rossing K, Hovind P, Rossing P, Tarnow L: Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points. Semin Nephrol 2004;24:147-157.
4. Remuzzi G, Chiurchiu C, Ruggenenti P: Proteinuria predicting outcome in renal disease: nondiabetic nephropathies (REIN). Kidney Int Suppl 2004;92:S90-S96.
5. Remuzzi G, Ruggenenti P, Benigni A: Understanding the nature of renal disease progression. Kidney Int 1997;51:2-15.
6. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S, de Jong PE, de Zeeuw D, Lau J, Levey AS: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001;135:73-87.
7. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.
8. Remuzzi G, Ruggenenti P, Perico N: Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med 2002;136:604-615.
9. Wolf G: Link between angiotensin II and TGF-beta in the kidney. Miner Electrolyte Metab 1998;24:174-180.
10. Yamamoto T, Noble NA, Miller DE, Border WA: Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis. Kidney Int 1994;45:916-927.
11. Bos H, Andersen S, Rossing P, De Zeeuw D, Parving HH, De Jong PE, Navis G: Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. Kidney Int Suppl 2000;75:S32-S37.
12. Schmidt S, Ritz E: The role of angiotensin I-converting enzyme gene polymorphism in renal disease. Curr Opin Nephrol Hypertens 1996;5:552-555.
13. van Essen GG, Rensma PL, de Zeeuw D, Sluiter WJ, Scheffer H, Apperloo AJ, de Jong PE: Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy. Lancet 1996;347:94-95.
14. Andersen S, Tarnow L, Cambien F, Rossing P, Juhl TR, Deinum J, Parving HH: Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? Kidney Int 2002;62:192-198.
15. Andersen S, Tarnow L, Cambien F, Rossing P, Juhl TR, Deinum J, Parving HH: Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? Diabetes Care 2003;26:1501-1506.
16. Park HC, Choi SR, Kim BS, Lee TH, Kang BS, Choi KH, Lee HY, Han DS, Ha SK: Polymorphism of the ACE gene in dialysis patients: overexpression of DD genotype in type 2 diabetic end-stage renal failure patients. Yonsei Med J 2005;46:779-787.
17. Ha SK, Seo JK: Insertion/deletion polymorphism in ACE gene as a predictor for progression of diabetic nephropathy. Kidney Int Suppl 1997;60:S28-S32.
18. Park SY, Paik HY, Skinner JD, Spindler AA, Park HR: Nutrient intake of Korean-American, Korean, and American adolescents. J Am Diet Assoc 2004;104:242-245.
19. Remuzzi A, Puntorieri S, Battaglia C, Bertani T, Remuzzi G: Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. J Clin Invest 1990;85:541-549.
20. Taal MW, Chertow GM, Rennke HG, Gurnani A, Jiang T, Shahsafaei A, Troy JL, Brenner BM, Mackenzie HS: Mechanisms underlying renoprotection during renin-angiotensin system blockade. Am J Physiol Renal Physiol 2001;280:F343-F355.
21. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy: The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997;349:1857-1863.
22. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G: Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998;352:1252-1256.
23. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999;354:359-364.
24. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288:2421-2431.
25. Haas M, Yilmaz N, Schmidt A, Neyer U, Arneitz K, Stummvoll HK, Wallner M, Auinger M, Arias I, Schneider B, Mayer G: Angiotensin-converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease. Austrian Study Group of the Effects of Enalapril Treatment in Proteinuric Renal Disease. Kidney Blood Press Res 1998;21:66-69.
26. Moriyama T, Kitamura H, Ochi S, Izumi M, Yokoyama K, Yamauchi A, Ueda N, Kamada T, Imai E: Association of angiotensin I-converting enzyme gene polymorphism with susceptibility to antiproteinuric effect of angiotensin I-converting enzyme inhibitors in patients with proteinuria. J Am Soc Nephrol 1995;6:1676-1678.
27. Boonstra A, de Zeeuw D, de Jong PE, Navis G: Role of genetic variability in the renin-angiotensin system in diabetic and nondiabetic renal disease. Semin Nephrol 2001;21:580-592.
28. Yoshida H, Mitarai T, Kawamura T, Kitajima T, Miyazaki Y, Nagasawa R, Kawaguchi Y, Kubo H, Ichikawa I, Sakai O: Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 1995;96:2162-2169.
29. Vleming LJ, van der Pijl JW, Lemkes HH, Westendorp RG, Maassen JA, Daha MR, van Es LA, van Kooten C: The DD genotype of the ACE gene polymorphism is associated with progression of diabetic nephropathy to end stage renal failure in IDDM. Clin Nephrol 1999;51:133-140.
30. Haneda M, Kikkawa R, Sakai H, Kawamori R: Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy. Diabetes Res Clin Pract 2004;66:87-95.
31. Jacobsen P, Rossing K, Rossing P, Tarnow L, Mallet C, Poirier O, Cambien F, Parving HH: Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney Int 1998;53:1002-1006.
32. Remuzzi A, Perico N, Sangalli F, Vendramin G, Moriggi M, Ruggenenti P, Remuzzi G: ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. Am J Physiol 1999;276:F457-F466.
33. Woo KT, Lau YK, Wong KS, Chiang GS: ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis. Kidney Int 2000;58:2485-2491.
34. Gansevoort RT, de Zeeuw D, de Jong PE: Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994;45:861-867.
35. Buter H, Navis G, Dullaart RP, de Zeeuw D, de Jong PE: Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM. Nephrol Dial Transplant 2001;16:771-775.
36. Houlihan CA, Allen TJ, Baxter AL, Panangiotopoulos S, Casley DJ, Cooper ME, Jerums G: A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care 2002;25:663-671.
37. Buter H, Hemmelder MH, Navis G, de Jong PE, de Zeeuw D: The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998;13:1682-1685.
38. van der Kleij FG, Schmidt A, Navis GJ, Haas M, Yilmaz N, de Jong PE, Mayer G, de Zeeuw D: Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: role of sodium status. Kidney Int Suppl 1997;63:S23-S26.
39. Laverman GD, Henning RH, de Jong PE, Navis G, de Zeeuw D: Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria. Am J Kidney Dis 2001;38:1381-1384.
40. Andersen S, Rossing P, Juhl TR, Deinum J, Parving HH: Optimal dose of losartan for renoprotection in diabetic nephropathy. Nephrol Dial Transplant 2002;17:1413-1418.
41. Crowe AV, Howse M, Vinjamuri S, Kemp GJ, Williams PS: The antiproteinuric effect of losartan is systemic blood pressure dependent. Nephrol Dial Transplant 2003;18:2160-2164.